Author: Ravi Shankar

MONTRÉAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the appointment of Mr. Guillaume Bacconnier to its Board of Directors, effective immediately.

Mr. Bacconnier holds a Master’s degree in Polymer Science. Throughout his career, he has held various commercial and operational leadership positions in seven countries. He has been a member of the Rio Tinto Group for approximately 20 years. He currently serves as General Manager of Évolys Québec Inc., a joint venture formed by Rio Tinto and Aymium, a technology company, to produce biocarbon in Canada.

In addition, the Company has approved the grant of 150,000 incentive stock options to Mr. Bacconnier. One-third of these stock options will vest immediately, with the remaining stock options subject to a two-year vesting period. The options have a term of seven years and an exercise price of $0.08 per share. The stock options were granted pursuant to the Company’s Stock Option Plan and are subject to applicable securities laws and the policies of the TSX Venture Exchange.

Message from NioBay’s President and CEO

“I am very pleased to welcome Guillaume to the Company’s Board of Directors. His drive, extensive experience in large corporations, and involvement in various strategic minerals projects will bring valuable expertise to help us advance through NioBay’s next stages of development.”

About NioBay Metals Inc.

NioBay aims to become a leader in the development of mine(s) with low carbon consumption and responsible water and wildlife management practices while prioritizing the environment, social responsibility, good governance, and the inclusion of all stakeholders. Our top priority, which is critical to our success, is the consent and full participation of the Indigenous communities in whose territories and/or on ancestral lands we operate.

In addition to other properties, NioBay holds a 100% interest in the James Bay Niobium Project located 45 km south of Moosonee, in the Moose Cree Traditional Territory of the James Bay Lowlands in Ontario. NioBay also holds an 80.2% interest in the Crevier Niobium and Tantalum project located in Québec and on the Nitassinan (ancestral territory) of the Pekuakamiulnuatsh First Nation. 

About Niobium

Niobium is a naturally occurring element. It is a metal that is ductile, malleable and highly resistant to corrosion. Because it enhances properties and functionalities, niobium is used in a wide range of materials and applications in the Mobility, Structural and Energy sectors. Niobium transforms materials. When added to materials like steel, glass and aluminum castings, niobium makes them more efficient and lowers environmental impacts, while also increased value.

About Tantalum

One of the main uses of tantalum is in the production of electronic components. Tantalum (Ta) causes no immune response in mammals, so has found wide use in the making of surgical implants. It can replace bone, for example, in skull plates; as foil or wire, it connects torn nerves; as woven gauze it binds abdominal muscle. Tantalum alloys can be extremely strong and have been used for turbine blades, rocket nozzles and internal combustion engines.

Cautionary Statements Regarding Forward-Looking Information
Certain statements in this news release constitute “forward-looking information” within the meaning of Canadian securities laws. Forward-looking statements and information may be identified by such terms as “anticipates”, “believes”, “targets”, “estimates”, “plans”, “expects”, “budget”, “scheduled”, “forecasts”, “intends”, “may”, “will”, “could” or “would” or the negative connotation thereof. These statements are necessarily based on a number of management’s beliefs, assumptions, and opinions as of the date they are made and are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected, including those risks set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca) under the Company’s issuer profile. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Although the assumptions made by the Company in providing forward-looking information is considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate and actual results and future events could differ materially from those anticipated in such information. The Company assumes no obligation to update these forward-looking statements should management’s beliefs, estimates, or opinions, or other factors, change, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. 

FOR MORE INFORMATION, CONTACT:

NioBay Metals Inc. Jean-Sebastien David, geo. President & Chief Executive Officer Tel.: 514 866-6500 jsdavid@niobaymetals.com www.niobaymetals.com

Kimberly Darlington Investor Relations kimberly@refinedsubstance.com Tel: 514-771-3398

VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Encore Technologies Corp. (“Encore” or the “Company”) (CSE: ENCR) is pleased to announce the appointment of Lieutenant-General (Retired) Michael (Mike) Hood, CMM, CD, former Commander of the Royal Canadian Air Force, as Strategic Advisor to the Company.

Mr. Hood brings more than three decades of military leadership, including senior responsibilities in force development, international security policy and strategic operations. As Strategic Advisor, he will support Encore’s activities and opportunities in the space sector through strategic advice, business development, and government and industry relationships. His appointment is particularly relevant to the Company’s previously announced strategic investment in Solstar Space Company (“Solstar”).

Highlights

• Former Royal Canadian Air Force Commander Michael Hood appointed Strategic Advisor.
   
• Mr. Hood brings more than three decades of military and aerospace leadership, including extensive experience in capability planning, mission requirements and the adoption of mission-critical technologies.
   
• Appointment strengthens Encore’s capabilities in business development and government and industry engagement as it advances its space-sector strategy and relationship with Solstar.

“Mike brings the perspective of someone who has led a national air force and understands how operational requirements shape the adoption of new technology,” said Stephen Kukucha, Chief Executive Officer of Encore. “His experience will be particularly valuable as we develop our space-sector strategy and build on our relationship with Solstar. Mike will help us assess business opportunities, develop government and industry relationships, and identify where Encore can contribute strategically.”

“Reliable communications are fundamental to effective operations, and the value of a new capability depends on how well it addresses the needs of the people using it,” said Mr. Hood. “I look forward to working with Encore on its space-sector strategy and helping the team build productive relationships across government and industry. The Company’s relationship with Solstar provides a compelling focus for that work as we assess opportunities in space communications and infrastructure.”

Strategic Rationale

Encore closed its strategic investment of approximately US$1.16 million in Solstar on August 4, 2026. Solstar is a U.S.-based company developing communications hardware, software and services for spacecraft and other space infrastructure.

Mr. Hood’s experience in military operations, capability planning and international security cooperation is expected to provide valuable perspective as Encore evaluates opportunities associated with its relationship with Solstar, including the needs of prospective commercial and government customers and potential business development and industry collaborations.

Advisory Role

As Strategic Advisor, Mr. Hood will focus on Encore’s activities and opportunities in the space sector. His role will include:

• Advising on the Company’s space-sector activities and opportunities, including those associated with its relationship with Solstar;
   
• Contributing to business development through the identification and assessment of potential commercial opportunities and collaborations in the space sector; and
   
• Supporting the development of government and industry relationships relevant to Encore’s space-sector activities.

About Michael Hood

Lieutenant-General (Retired) Michael Hood served as Commander of the Royal Canadian Air Force from 2015 to 2018, concluding a Canadian Armed Forces career that began in 1985. His earlier appointments included Deputy Commander of the Royal Canadian Air Force, Director of the Strategic Joint Staff, Director General Air Force Development and Deputy Director General of International Security Policy. He also commanded 8 Wing Trenton and both 429 and 436 Transport Squadrons.

Mr. Hood qualified as an Air Combat Systems Officer in 1988 and served primarily on the C-130 Hercules, as well as in an electronic warfare role on the CC-144 Challenger. He holds a master’s degree in international relations from Auburn University and completed professional military education in Canada and the United States. He is a Commander of the Order of Military Merit.

In the private sector, Mr. Hood served as Chief of Staff of the JDS Group of Companies and subsequently as President of JDS Operational Technologies. He joined Bluesky Strategy Group as a Senior Associate in 2023 and is a Principal at MH2 Advisory Services, a firm specializing in federal government relations and strategic advice. His commercial advisory work includes innovative technologies, government procurement, operational resilience and corporate strategy.

Grant of Stock Options

The Company also announces that it has granted an aggregate of 400,000 incentive stock options (the “Options”) to an officer and a consultant of the Company. Each Option entitles the holder to acquire one common share of the Company at an exercise price of C$0.35 for a period of three years from the date of grant.

The Options will vest in two equal instalments, with 50% vesting six months after the grant date and the remaining 50% vesting twelve months after the grant date, subject to the terms of the Company’s stock option plan and the applicable option agreements. The Options were granted in accordance with the Company’s stock option plan and are subject to applicable securities laws and CSE policies.

About Encore Technologies Corp.

Encore Technologies Corp. evaluates and advances technology businesses focused on intelligent infrastructure. The Company’s strategy includes investments and partnerships in technologies that can enhance connectivity, improve operational efficiency and support resilient infrastructure across established and emerging markets.  

For further information contact:
Stephen Kukucha
Chief Executive Officer
Tel: (604) 398-4786

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes statements regarding, among other things, the Company’s business strategy, future development plans, expected operational initiatives, and other statements that are not historical facts. Forward-looking information is generally identified by words such as “expects,” “intends,” “anticipates,” “believes,” “plans,” “estimates,” “may,” “could,” “would,” “should,” and similar expressions. Forward-looking information reflects management’s current beliefs and assumptions and is subject to a number of known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update or revise forward-looking information except as required by applicable law.

The CSE has neither approved nor disapproved the contents of this news release. The CSE does not accept responsibility for the adequacy or accuracy of this news release.

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026

ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity

Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies

SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China’s National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene’s proprietary SAFEbody® precision masking technology. Adagene expects to initiate a first-in-human Phase 1 study of ADG138 for the treatment of advanced solid tumors in the fourth quarter of 2026.

“The NMPA’s rapid approval of our IND application for ADG138 speaks to the strength of the preclinical package and allows us to bring a differentiated, double-masked T-cell engager into the clinic for patients with HER2-expressing solid tumors,” said Peter Luo, Ph.D., Chairman and President of R&D at Adagene. “In preclinical studies, ADG138 achieved potent, T-cell mediated anti-tumor activity in Enhertu (DS-8201) resistant tumor models while retaining a substantial reduction in cytokine release and a wider therapeutic window relative to an unmasked T-cell engager. We look forward to advancing ADG138 into first-in-human studies and building on the safety and efficacy profile we believe our SAFEbody platform can bring to T-cell engagers in solid tumors.”

A Phase 1, first-in-human, open-label clinical study is designed to evaluate the safety and preliminary efficacy of ADG138 in patients with advanced solid tumors as well as to determine the recommended dose for Phase 2.

About ADG138

ADG138 is a double-masked HER2×CD3 bispecific T cell engager designed using Adagene’s SAFEbody® precision masking technology, which covalently links masking peptides to both the HER2- and CD3-binding arms of the molecule. In its inactivated state, ADG138 is designed to minimally bind HER2-expressing cancer cells and T cells; the molecule becomes activated within the tumor microenvironment and engages T cells to selectively kill HER2-expressing tumor cells while limiting off-target toxicity.

Preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting in 2022 showed that double-masked ADG138 achieved approximately 220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, yet translating to high efficiency in T cell-mediated tumor cell killing and T cell activation. ADG138 drove regression in both HER2-high and HER2-low tumor models, including a model refractory and/or resistant to the Enhertu (DS-8201), and showed synergistic anti-tumor activity in combination with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. In addition, ADG138 was tolerated at doses over 300-fold higher than an unmasked T-cell engager, with markedly reduced cytokine release and a favorable pharmacokinetic profile, including a longer apparent half-life and higher systemic exposure than the parental molecule.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene’s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding certain clinical results of ADG138, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investor Contacts:
Raymond Tam
Raymond_tam@adagene.com

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com

Media Contact:
Ian Stone
LifeSci Communications
istone@lifescicomms.com

117 soil and 34 rock chip samples collected at the Vent Copper Project

CALGARY, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Northern Discovery Metals Inc. (CSE: NOR) (FSE: M1V0) (“Northern Discovery” or the “Company”) is pleased to provide an update on its ongoing Stage 1 exploration program at the Vent Copper Project (“Vent” or the “Project”), located in the Alberni Mining Division on Vancouver Island, British Columbia. The field team has collected 117 soil samples and 34 rock chip samples to date as part of a program of geological mapping, prospecting and targeted sampling. The Company holds an option to acquire up to a 100% interest in the Project.

The work is being carried out by Geomap Exploration Inc. and follows the Company’s September 3, 2026 mobilization announcement. Stage 1 is designed to refine exploration priorities by examining the relationships between previously identified mineralization responses, geological contacts, structures, alteration and veining. The program was designed to initially focus on the Vent-Ken and Sentinel Peak areas and includes ground checks of priority magnetic and VLF-EM features.

Fieldwork to date has included systematic soil sampling and the examination and sampling of selected rock exposures. Preliminary field descriptions include volcanic and intrusive rocks, with localized chlorite alteration, quartz veining and minor pyrite noted at selected rock sampling sites. These observations will help inform the geological interpretation of the sampling results. Laboratory analysis is required to determine the potential for any metal content, and no assay results from the current program are reported in this release.

“The field team is building the geological and geochemical dataset we need to guide the next stage of exploration at Vent,” said Jared Suchan, Ph.D., P.Geo., Chief Executive Officer and Director of Northern Discovery Metals. “Our priority is to bring the sampling, geological observations and existing geophysical information together to identify where more detailed follow-up is warranted. This systematic approach will help us direct future work toward the strongest targets.”

Qualified Person Statement

Jared Suchan, Ph.D., P.Geo., Chief Executive Officer and Director of the Company, and a “Qualified Person” within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical contents of this news release.

For a further discussion of the Company’s QA/QC and data verification procedures and processes, please see the technical report entitled, Technical Report on the Vent Copper Property, Alberni Mining Division, British Columbia, Canada, NTS Map 092F03W,” dated July 22, 2026, a copy of which may be obtained under the Company’s profile at www.sedarplus.ca.The Property is an exploration-stage mineral property with no current mineral resource or mineral reserve estimates.

About Northern Discovery Metals Inc.

Northern Discovery Metals Inc. is a mineral exploration company focused on the acquisition, exploration and advancement of mineral properties in Canada. The Company is exploring for copper at its Vent Project on Vancouver Island, British Columbia. Northern Discovery Metals intends to advance the Project through systematic exploration and evaluation of its mineral potential.

On Behalf of the Board of Directors

Jared Suchan

Chief Executive Officer and Director

Phone: (604) 294-3020

Email: info@northerndiscoverymetals.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential”, “scheduled”, “targeted”, “may”, “will”, “could”, “would” and similar expressions, or statements that certain events or conditions “will”, “may” or “could” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the expected timing, duration, scope and focus of the Stage 1 exploration program at the Property; the proposed geological mapping, prospecting and rock and soil sampling; the evaluation and follow-up of geochemical responses, magnetic and VLF-EM responses and other evidence encountered during the program; the integration of program results with existing geological, geochemical and geophysical information; the refinement of the Company’s geological model and ranking of priority areas; the potential identification of coherent geological and geochemical targets; the possible undertaking of focused induced-polarization or other ground geophysical work; the potential refinement and ranking of drill targets; and the Company’s plans to systematically explore, evaluate and advance the Property. 

Forward-looking statements are based on management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release, including assumptions regarding the availability of personnel, contractors, equipment, supplies and financing on acceptable terms; the accuracy, reliability and completeness of historical and existing geological, geochemical and geophysical data; the ability to obtain and maintain all required permits, approvals and access arrangements; suitable weather, access and field conditions; the performance of Geomap and other contractors in accordance with applicable work plans; and the absence of material adverse changes in applicable laws, commodity prices, market conditions or the Company’s business and financial position. Although the Company considers these assumptions reasonable based on information currently available, they may prove to be incorrect. 

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those anticipated in such statements. These risks and uncertainties include, among others: delays, interruptions, changes in scope or cost overruns affecting the exploration program; adverse weather, access, terrain, wildfire or other field conditions; the inability to secure or maintain permits, approvals, land access, personnel, contractors, equipment, supplies or sufficient financing; contractor performance and operational risks; accidents, environmental incidents and other hazards inherent in mineral exploration; the possibility that sampling, mapping, prospecting or geophysical work will not verify or explain historical anomalies, identify mineralization or produce coherent targets; the risk that geochemical or geophysical anomalies are not indicative of economic mineralization; uncertainties inherent in geological interpretation, data verification and the estimation of exploration potential; the preliminary nature of exploration results and the possibility that results from one area are not representative of the Property as a whole; title, option agreement and property access risks; fluctuations in commodity prices and market conditions; changes in laws, regulations, permitting requirements or government policies; competition for capital, personnel and equipment; and the additional risks described in the Company’s continuous disclosure filings with applicable securities regulatory authorities. There can be no assurance that the exploration program will proceed as currently contemplated, be completed on the expected timeline or at all, or achieve the anticipated results. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof, and the Company undertakes no obligation to update or revise them to reflect new events or circumstances, except as required by applicable securities laws. 

The CSE has neither approved nor disapproved the information contained herein.

New Boise facility will help prepare the next generation of technicians for careers supporting advanced semiconductor manufacturing

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — With demand for skilled semiconductor technicians continuing to outpace supply, ABM (NYSE: ABM), a leading provider of facility, operations, production maintenance, and infrastructure solutions, today announced the grand opening of the ABM Technical Training Center in Boise, Idaho, one of the nation’s fastest-growing semiconductor manufacturing hubs. The center draws on the specialized semiconductor expertise ABM added through its acquisition of WGNSTAR earlier this year, further expanding ABM’s technical training capabilities to support the industry’s growing workforce needs.

The Boise center extends ABM’s existing semiconductor training footprint in Austin, Texas, and is expected to have capacity for approximately 500 participants annually at launch. It features a comprehensive, industry-aligned training program that combines instructor-led classroom learning, hands-on technical labs, and virtual reality simulations covering the core systems that support semiconductor manufacturing.

Developed by ABM semiconductor subject matter experts and endorsed by SEMI, the global industry association serving the electronics design and manufacturing supply chain, the program provides participants with the foundational knowledge and practical skills needed to succeed in entry-level technical roles across semiconductor manufacturing environments. Graduates will also earn an industry-recognized Swagelok certification as part of the curriculum.

“The future of American semiconductor manufacturing depends not only on building more fabrication plants, but on developing the workforce to operate them,” said Ed Marcil, President of Manufacturing & Distribution at ABM. “Across the industry, demand for qualified and credentialed technicians continues to outpace the available workforce, creating one of the biggest challenges facing manufacturers today. Through ABM’s new Technical Training Center, we are helping create faster pathways into technical careers because the industry’s ability to grow depends on the people who keep these operations running.”

Governor Brad Little added, “Idaho is a national leader in advanced semiconductor manufacturing, and investments like ABM’s Technical Training Center ensure we are preparing Idahoans to fill the good-paying jobs that industry is creating. By bringing hands-on training and industry-recognized credentials to Boise, ABM is helping build the skilled workforce we need to support innovation, strengthen our economy, and keep Idaho at the forefront of America’s semiconductor future. I appreciate ABM’s investment in Idaho and its commitment to preparing the next generation of technicians.”

Designed to complement existing education and workforce initiatives, the employer-agnostic program prepares participants for technical careers supporting semiconductor manufacturers, equipment suppliers, and facilities operators. By providing industry-aligned training before participants enter semiconductor environments, the program helps strengthen workforce readiness and better prepare technicians to contribute on the job.

About ABM

ABM (NYSE: ABM) is one of the world’s largest providers of integrated operations, production maintenance, facility, and infrastructure solutions. Through its manufacturing and distribution business, ABM helps many of the world’s leading manufacturers optimize production environments with specialized operations, maintenance, infrastructure, and workforce solutions.

ABM provides comprehensive support to the semiconductor industry, helping clients maintain critical manufacturing environments, improve operational performance, and develop the skilled workforce needed to support continued industry growth.

With more than 100,000 team members and over $8 billion in annual revenue, ABM serves clients across manufacturing and distribution, semiconductor, mission critical, commercial real estate, aviation, education, and other essential industries. ABM: Driving possibility, together.

For more information, visit www.abm.com.

Media contact:
Michael Valentino 
media@abm.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e4ed491-5bd6-4744-aa50-81a26c04df51

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants.

Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasdaq listing.

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully exercised at the $6.43 strike price.

Key dates and terms:

• Expiration date: September 30, 2026 5PM ET
• Strike price: $6.43 per warrant
• Warrants outstanding: 910,904
• No extension. No repricing.

Shareholders and warrant holders are advised to act before the deadline if they intend to exercise. Nutriband will continue to provide updates on Company developments in the coming weeks.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

Novacium was selected based on the performance of its very high-capacity GEN 3 and GEN 4 cylindrical cells, designed for high-capacity battery applications. The contract was awarded at the end of June 2026

MONTREAL and SOLAIZE, France, Sept. 22, 2026 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08) is pleased to inform its shareholders that its strategic partner, NOVACIUM SAS, a French deep-tech company specializing in green engineering of materials for energy applications, has announced that the French Army Technical Section (“STAT”) awarded it a contract ^[1] at the end of June 2026 for the development and supply of high-capacity prototype batteries to be evaluated in tactical radios. For procedural reasons, the award could not be announced prior to today.

From Initial Evaluation to Contract Award: More Than Eighteen Months of Technical Collaboration

In August 2024, STAT, the French Army organization responsible for evaluating and qualifying equipment for land forces, contacted Novacium after reviewing published results from cells developed using its silicon-based anode material. The organization sought to evaluate the possibility of integrating Novacium’s cells into the batteries used in its tactical radios.

Following six months of internal development, Novacium’s teams developed two battery prototypes, which were provided to STAT in April 2025. The initial results were conclusive: with comparable form factors and interfaces, energy capacity increased by 23% compared with the reference battery.

Image 1) Photos illustrating the use of Novacium’s high-capacity batteries

Building on these results, in September 2025 Novacium met with France’s Directorate General of Armaments (DGA), Defence Innovation Agency (AID), and STAT to propose a work program to develop very high-capacity prototype batteries.

Several months of discussions followed to refine the program around an ambitious objective: significantly increasing, or potentially doubling, the energy capacity of tactical radio batteries without modifying existing connectors, chargers, or interfaces. This work resulted in a contract award to Novacium at the end of June 2026.

Selection Based on the Performance of Novacium’s High-Capacity Cells

Novacium was selected based on the performance of its very high-capacity GEN 3 and GEN 4 cylindrical cells, designed for high-capacity battery applications. This distinctive energy density made it possible to propose a solution capable of meeting STAT’s objective: significantly increasing the operating time of tactical radios without disrupting existing charging infrastructure, procedures or the logistics chain.

The contract provides for delivery in successive batches, structured around operational field feedback (RETEX). The first batch of prototypes will undergo an evaluation campaign under operational conditions, after which STAT and Novacium will jointly prepare a detailed RETEX. Lessons learned from this evaluation will guide design adjustments before production of a second batch that will better reflect a series-production configuration.

Image 2) Novacium battery for tactical radios and GEN 4 21700 cells

“The award of this contract by STAT represents an important recognition of Novacium’s expertise in designing high-performance cells and batteries for demanding environments. We were selected because our GEN 3 and GEN 4 cells offer a distinctive energy density capable of meeting particularly demanding specifications. This program illustrates our strategy: applying our materials and battery expertise to critical defence and security applications,” said Dr. Jed Kraiem, Ph.D., Chief Operating Officer of Novacium.

Potential Applications with Other Allied Forces

The expertise deployed under this program (high-capacity cell integration, battery management system adaptation and enclosure design) could be applied to other battery formats for tactical radios used by the armed forces of NATO member countries. A successful evaluation by STAT could serve as a technical reference to support this approach. However, each adaptation would remain subject to the relevant platform’s specific requirements, qualification testing, and separate procurement decisions.

“Novacium’s selection by the French Army’s technical organization responsible for equipment evaluation and qualification represents an important step in validating its expertise,” said Bernard Tourillon, President and CEO of HPQ Silicon Inc., which serves as President of Novacium. “If the evaluation phase confirms the expected performance, this program could become a relevant technical reference for presenting the solution to other allied forces with comparable requirements. For HPQ, every advance Novacium makes in the defence sector also strengthens the strategic value of our 36.8% interest in Novacium, as well as the potential to commercialize in North America the technologies covered by our licensing agreement.”

This contract is part of the continued development of Novacium’s activities in the defence and autonomous systems sectors. It follows the August 19, 2026, announcement of a first order for battery packs intended to power drones to be delivered to a French Army regiment through LN’INNOV.

Additional Information:

[1] A “marché,” in the context of French public procurement, refers to a paid contract entered between a public purchaser and an economic operator to meet a requirement for works, supplies or services in exchange for a price or equivalent consideration. In this case, the contract awarded to Novacium covers the development and supply, in successive batches, of prototype batteries intended for evaluation by STAT. The financial terms and quantities covered by the contract are subject to confidentiality obligations and are not disclosed.

About Novacium SAS

Novacium is a French deep-tech company based in Solaize, specializing in the development and production of silicon-based anode materials for lithium-ion batteries using a proprietary process. Novacium also designs custom battery cells and packs for demanding applications, particularly in the defence, aerospace and portable energy sectors.

About HPQ Silicon

HPQ Silicon Inc. is a Quebec-based industrial issuer listed on the TSX Venture Exchange (TSX-V: HPQ), focused on innovation in advanced materials and the development of critical processes.

HPQ holds a strategic 36.8% interest in Novacium, its research, development and commercialization partner. Together, HPQ and Novacium are developing next-generation silicon-based anode materials (Gen3 and Gen4) for batteries, pursuing the commercialization of ENDURA+ lithium-ion cells, and developing innovative technologies for clean hydrogen production and the energy recovery of waste materials. HPQ holds the exclusive rights to commercialize these technologies in North America.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements based on certain assumptions regarding technological performance, market demand, permitting, financing, supply chains and economic conditions. These statements involve significant risks, including delays, regulatory issues, competition, availability of financing and macroeconomic uncertainties. Actual results could differ materially from those anticipated. Detailed risk factors are presented in HPQ’s Annual Information Form available on SEDAR+. Forward-looking statements are provided solely to outline management’s future expectations and objectives. A more detailed cautionary note regarding forward-looking information related to the HPQ Endura+ batteries project is available for download [here]. Additional information regarding the Company is available on SEDAR+ (www.sedarplus.ca) and on the Company’s website at www.hpqsilicon.com/.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Contact Information

NOVACIUM SAS
Dr. Jed Kraiem, Ph.D., Chief Operating Officer
info@novacium.com

HPQ Silicon Inc.
Bernard J. Tourillon, BAA, MBA, President and CEO
info@hpqsilicon.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/a8db8169-0afd-4ee5-945b-d6606238f077
https://www.globenewswire.com/NewsRoom/AttachmentNg/a4942b78-d043-4fe3-9c99-91b31b691b30 

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, will host a live webcast and product demo for financial analysts and investors on Wednesday, October 14, 2026, at 12:00 p.m. Eastern Time.

The webcast will provide a comprehensive recap of the strategic product introductions and platform capabilities unveiled at Navigate, SailPoint’s premier annual identity security conference.

The webcast will be available on SailPoint’s website at investor.sailpoint.com.  A replay of the webcast will be available on the investor relations website for one year.

Additionally, keynotes and mainstage sessions live from Navigate in Austin (October 5–8) will be streamed in real-time, learn more at sailpoint.com/navigate/austin.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Investor Relations Contact
Scott Schmitz, SVP IR
ir@sailpoint.com

Media Relations Contact
Shannon Paulk, Sr. Manager, Corporate Communications
shannon.paulk@sailpoint.com

• Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027
• Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential investigators
• Ongoing collaboration with the TSC Alliance and the broader TSC community is intended to support patient engagement and study execution

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.

“With the clinical hold lifted, we can now execute our development plan for simufilam in TSC-related epilepsy,” said Rick Barry, President and Chief Executive Officer of Filana. “While on hold, we completed key trial-readiness activities, including engaging a leading clinical research organization, identifying clinical trial sites, and recruiting potential investigators. With investigational drug supply in place, implementation of our Phase 2a study of simufilam is now able to progress expeditiously toward site initiation and patient enrollment.”

“Drug-resistant epilepsy remains a challenge for a majority of individuals affected by TSC,” said Kari Luther Rosbeck, President and Chief Executive Officer of the TSC Alliance. “Research investigating different molecular pathways involved in TSC offers hope for potential new options for those living with the disease. The TSC Alliance applauds Filana for their innovative work in exploring a new target mechanism and their plans to launch a clinical trial to test the effectiveness of that potential new treatment to help address a major unmet need for the TSC community.”

Planned Phase 2a Trial Design

Filana’s Phase 2a study is a 16-week multicenter, randomized, double-blind clinical trial to evaluate two doses of simufilam in patients with refractory TSC-related seizures. The study is planned to be conducted at 13 sites in the U.S. with a target enrollment of 40 subjects aged 12 to 55. All subjects who complete the double-blind treatment phase are eligible to participate in a 48-week extension study.

The study is designed to assess safety, tolerability, pharmacokinetics, and seizure-related measures, including seizure frequency, seizure intensity and duration, nighttime seizures, and sleep-related outcomes. Data from the study are expected to help inform the development path for simufilam in TSC-related epilepsy, including the design of future studies in younger patient populations.

Scientific Rationale

Simufilam is an oral small molecule intended to modulate the filamin A protein. The clinical evaluation of simufilam in TSC-related epilepsy is supported by findings from two preclinical mouse models. Initial studies were conducted in the laboratory of Angélique Bordey, PhD, Rothberg Professor of Neurosurgery at Yale School of Medicine and Senior Vice President, Neuroscience at Filana. Those studies showed that simufilam reduced seizure frequency in a mouse model of focal onset seizures involving TSC-related pathology¹. In a separate study conducted with the TSC Alliance Preclinical Consortium using a well-accepted TSC-knockout mouse model, simufilam attenuated the progression of seizure activity in a dose-dependent manner².

Filana holds an exclusive worldwide license from Yale University to intellectual property supporting the use of simufilam in TSC-related epilepsy.

About TSC and TSC-Related Epilepsy

TSC is a rare genetic disorder resulting from a mutation in the TSC1 or TSC2 gene. These mutations affect the mechanistic target of rapamycin (mTOR) pathway and can cause tumors to grow in multiple organs^3,4. Epilepsy is the most common health issue affecting the TSC community, with 80% to 90% of TSC patients experiencing seizures⁵. TSC-related epilepsy affects approximately 45,000 people in the U.S.^1,3. Most patients start having seizures within their first year of life¹. Even with multiple approved treatments, more than 60% of TSC patients remain refractory to antiepileptic therapy⁶.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (NASDAQ: FLNA), is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

For more information, please visit: https://www.FilanaTx.com

References:

1. Zhang L, Huang T, Teaw S, Nguyen LH, Hsieh LS, Wong X, Burns LH, Bordey A. Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations. Science Translational Medicine. 2020;12(531):eaay0289. DOI: 10.1126/scitranslmed.aay0289
2. Stansley B, Islam MM, Aguiar DJ, Fuchs Z, Catron M, Morairty S, et al. The small molecule simufilam dose-dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex. Epilepsia. 2026;00:1–13. DOI: 10.1002/epi.70227
3. https://www.tscalliance.org/understanding-tsc/what-is-tsc/
4. https://www.tscalliance.org/understanding-tsc/genetics/
5. Crino P, Nathanson K, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356. DOI: 10.1056/NEJMra055323
6. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241. DOI: 10.1111/j.1528-1167.2009.02474.x

For More Information Contact:
Investors
Mike Moyer
mmoyer@lifesciadvisors.com

Filana Therapeutics
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@FilanaTx.com
IR@FilanaTx.com

Cautionary Note Regarding Forward-Looking Statements:

This news release contains forward-looking statements that may include but are not limited to statements regarding: the timing and plans to initiate and conduct clinical studies with simufilam in TSC-related epilepsy; the design, structure, duration, objectives, endpoints, patient population, conduct, enrollment, completion, and potential results of our planned Phase 2a clinical trial; our ability to work with clinical research organizations, clinical sites, patient advocacy organizations, and the TSC community to advance the trial efficiently; the potential for simufilam as a treatment for TSC-related epilepsy and other potential indications; and the timing of anticipated milestones, including announcing study sites and screening patients. These statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, “pending”, “plan”, “possible”, “potential”, “prepares for”, “will”, and other words and terms of similar meaning.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to our ability to initiate, enroll, conduct, and complete the planned Phase 2a study of simufilam in TSC-related epilepsy; our ability to engage clinical trial sites and participants; our ability to work effectively with clinical research organizations, vendors, investigators, patient advocacy organizations, and the TSC community; potential changes to the clinical trial protocol, trial design, endpoints, timing, patient population, or development plans; our ability to generate clinical data that support further development of simufilam; risks inherent in drug discovery and development; and other risks specific to Filana Therapeutics, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.

All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.

Site II would add approximately $391 million in base-term contracted revenue to previously announced base-term contracted revenue of $1.25 billion for Site I. 

NEW YORK, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Host Digital Inc. (NYSE American: HOST) (“Host Digital” or the “Company”), a vertically integrated digital infrastructure company that develops, acquires, owns, and operates institutional-quality, RightScaled data centers for artificial intelligence (“AI”) and high-performance computing (“HPC”), began trading on Friday, September 18 on the NYSE American under the ticker symbol “HOST.”

Host Digital also announced that it has signed a Preferential Rights Agreement with its Sponsor, which provides Host Digital with a right of first offer and a right of first refusal on qualifying data center projects held by its Sponsor. Host Digital expects to acquire from the Sponsor a second data center facility, also located in northeast Oklahoma (“Site II”). The Sponsor has signed a 12-year take-or-pay lease for Site II, with a publicly traded AI cloud provider, for approximately 20 MW of gross / 16 MW of critical IT load, representing approximately $391 million in base-term rent, or approximately $819 million over a total 22-year term assuming all renewal options are exercised, which is expected to be supported by a lease backstop from an investment-grade publicly listed U.S.-based global technology company.

Any contribution of Site II remains subject to negotiation and the execution of definitive agreements, and no assurance can be given that it will occur.

TRANSACTION AND LEASE HIGHLIGHTS

• Merger completed: Host Digital completed its merger with Host Digital Infrastructure LLC on September 17, 2026. Following the Closing of the priced offering, HOST’s outstanding share count is 48,088,414, which implies a market capitalization of $384,947,754.07 as of market close on September 21, 2026.
• Trading as HOST: Shares began trading on the NYSE American under the ticker symbol “HOST” on Friday, September 18, 2026.
• Site I: With the closing of the merger, Site I is now owned by Host Digital. The fully executed 15-year, take-or-pay lease is for 55 MW gross / 43 MW of critical IT load, representing approximately $1.25 billion in base-term contracted revenue, or approximately $3.2 billion over a 30-year total term if all renewal options are exercised, and a Year 1 contracted revenue of $67 million, with delivery expected in the first quarter of 2027. The terms also include a 3.0% annual rent escalator with the tenant bearing operating expenses. The lease is expected to be supported by a lease backstop from an investment-grade publicly listed U.S.-based global technology company.
• Site II: Host Digital expects to acquire from the Sponsor a second data center facility, also located in northeast Oklahoma (“Site II”), pursuant to its rights under the Preferential Rights Agreement. The Sponsor has signed a 12-year take-or-pay lease with a publicly traded AI cloud provider for approximately 20 MW gross / 16 MW of critical IT load, representing approximately $391 million in base-term rent, or approximately $819 million over a total 22-year term assuming all renewal options are exercised, and Year 1 contracted revenue of $28.3 million. The terms also include a 2.5% annual rent escalator with the tenant bearing operating expenses. The lease is expected to be supported by a lease backstop from a different investment-grade publicly listed U.S.-based global technology company. The contribution of Site II remains subject to negotiation and the execution of definitive agreements.[1]
• Sponsor relationship: Under the Preferential Rights Agreement, Sponsor provided the Company with a 24-month exclusive right of first offer and right of first refusal on qualifying data center assets from the Sponsor’s pipeline, which includes an additional 450 MW of RightScaled data center assets with the potential ability to be delivered to tenants in 2027, as well as longer-term, “land and expand” growth from both grid and behind-the-meter expansions at existing sites, followed by the potential development of larger scale projects which may potentially be delivered to tenants in 2028 and beyond.
• Differentiated approach: Host Digital expects to target a combination of RightScaled, 20-100 MW grid-powered assets with existing or near-term electricity in place, which it expects to be able to deliver to tenants in 2026, 2027 and 2028, and which can potentially be expanded with additional utility capacity and behind-the-meter private grid generation, along with larger scale opportunities which may potentially be delivered in 2028 and beyond. This “barbell” approach aims to accelerate revenue by emphasizing speed to power, while maximizing opportunities for scale over time. The Company focuses on rapidly delivering “turnkey” facilities, which go beyond a typical powered shell to meet tenants, chipmakers and end users where they are, in what the Company considers a “sweet spot” of development cost and lease rates.

“Host Digital is entering the public markets with the three things that matter most in AI infrastructure today: access to power, contracted demand, and a model we can repeat,” said Shawn Matthews, Chairman of Host Digital. “At our initial site, we have 43 MW of critical IT load committed under a long-term lease. We now have started negotiations to acquire a second energized and leased facility. If we complete that acquisition, Host Digital expects to have approximately 59.3 MW of total contracted critical IT load and an aggregate of $1.64 billion in base-term contracted revenue across the two sites. Our listing on the New York Stock Exchange American gives us a public-markets platform to continue building that portfolio with discipline.”

“Infrastructure is ultimately constrained by how quickly operators can secure power and bring capacity online,” said Harmol Samra, Chief Executive Officer of Host Digital. “The Host Digital platform’s strategy addresses this constraint. We target acquiring sites where power is already flowing or available in the near term, then develop against long-term contracted demand, rather than building speculative capacity and hoping tenants follow. Site II is exactly the type of asset our RightScaled strategy was designed to capture: energized infrastructure, a modular design, contracted demand, and a defined path to tenant delivery.”

Host Digital’s development model centers on RightScaled sites of approximately 20 MW to 100 MW with grid power available today or in the near term, supplemented by behind-the-meter generation where appropriate, and developed against long-term contracted demand from strong or credit-enhanced counterparties. The strategy is designed to bring new capacity to market in months rather than years while avoiding many of the interconnection, permitting, and infrastructure constraints facing larger greenfield developments.

Host Digital expects to own and control the core physical infrastructure at each facility, including the real estate, power and interconnection rights, utility agreements, electrical systems, and cooling infrastructure. Tenants are expected to control their own compute infrastructure and model layers, allowing Host Digital to operate as the underlying digital infrastructure and real estate platform rather than taking technology or compute risk.

PREFERENTIAL RIGHTS AGREEMENT

In connection with the closing of the merger, Host Digital entered into a Preferential Rights Agreement with its Sponsor, an entity formed and controlled by the founders of Host Digital Infrastructure LLC. For 24 months, the agreement gives Host Digital exclusive rights of first offer and first refusal on data center assets the Sponsor acquires or develops and intends to place in a public company vehicle. The Sponsor’s potential pipeline includes four additional sites with more than 450 MW of gross power capacity targeted for delivery in 2026 and 2027, including more than 350 MW of grid power and more than 100 MW of behind-the-meter capacity.

Any contributions of additional sites remain subject to negotiation and the execution of definitive agreements, and no assurance can be given that they will occur.

EXPERIENCED LEADERSHIP

Shawn Matthews
Chairman of the Board of Directors

Shawn Matthews has over 30 years of management experience in public and private corporations, with diverse experience across energy and financial sectors. His leadership experience includes serving as CEO of Cantor Fitzgerald & Co. from 2009 to 2018; as founder and CEO of Hondius Energy; as CEO of Mercator Power; and as sponsor of Terrestrial Energy and a former member of its board of directors. Mr. Matthews has deep expertise and connectivity across the energy and real estate sectors, and capital markets more broadly, and brings strong governance leadership to HOST.

Harmol Samra
Chief Executive Officer

Harmol Samra has over a decade of experience in real estate private equity and digital infrastructure development, and previously served in roles at Starwood Capital and ICONIQ Capital in San Francisco and New York. At ICONIQ, Mr. Samra helped build and oversee IPI Partners, which grew to become one of the largest data center development platforms in the world. At the time of its sale to Blue Owl in 2024, IPI had a portfolio of 82 data centers comprising more than 2.2 gigawatts of leased capacity globally. Mr. Samra has significant expertise in developing real estate and digital infrastructure projects, and deep relationships across the AI/HPC and AI infrastructure universe. Mr. Samra previously held investment and investment banking roles, respectively, at PGIM, the global asset management business of Prudential Financial, Inc., with over $1.4 trillion in assets under management, and Morgan Stanley.

ABOUT HOST DIGITAL

Host Digital Inc. (NYSE American: HOST) develops, acquires, owns, and operates institutional-quality data centers in the United States that support AI and HPC workloads. The Company focuses on RightScaled sites of 20 MW to 100 MW with existing or near-term access to power, leased under long-term contracts to strong or credit-enhanced counterparties. Host Digital seeks to own and control the real estate, power, and data center infrastructure at each site, and provides turnkey facilities where tenants select and deploy their own compute infrastructure and model layers.

Through its wholly owned subsidiaries, the Company also operates a portfolio of 19 natural and organic grocery stores across six states under the Ada’s Natural Market, Paradise Health & Nutrition, Mother Earth’s Storehouse, Greens Natural Foods, Ellwood Thompson’s, and GreenAcres Market brands. Healthy Choice Wellness Corp.’s natural and organic grocery business continues to operate as a division of the Company following the merger.

For more information, visit www.hostdigital.ai.

Footnote

1. Any contribution of Site II remains subject to negotiation and the execution of definitive agreements, and no assurance can be given that it will occur.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed acquisition and development of one or more data center facilities, including the potential acquisition of Site II; the expected assets leases and other assets to be acquired from the Sponsor or any other third party; the timing of delivery of the Company’s data center facilities to tenants; anticipated contracted revenue, lease terms and renewal options; the Company’s development strategy and ability to execute and scale its business model; and the Sponsor’s potential pipeline and contribution of additional data center assets to the Company. Statements that are not historical facts are based on current estimates, assumptions and projections and are not guarantees of future performance. Words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “will,” “would,” “could” and similar expressions identify forward-looking statements, although not all forward-looking statements contain these words.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including risks relating to the completion of the offering on the anticipated terms or at all; the Company’s ability to satisfy the applicable listing requirements; the Company’s ability to successfully integrate the businesses and realize the anticipated benefits of the offering; the Company’s ability to obtain required financing, complete development and deliver capacity on schedule; and other factors described in the Company’s filings with the SEC, including under the header “Risk Factors” in Exhibit 99.2 to the Current Report on Form 8-K filed with the SEC on September 17, 2026. The Company undertakes no obligation to update these statements except as required by law.

MEDIA CONTACT
Jessica Starman
jessica@elev8newmedia.com
888-461-2233

INVESTOR CONTACT
Jason Assad
info@bridge-comms.com